{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:52:14Z","timestamp":1784019134663,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.021","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:28:39Z","timestamp":1762572519000},"page":"106-114.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-5219","authenticated-orcid":false,"given":"Adolfo Jes\u00fas","family":"S\u00e1ez-Mar\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hernandez-Ibarbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Medina","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes Mas","family":"Babio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cuervo","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-0900","authenticated-orcid":false,"given":"Jose Mar\u00eda","family":"Sanchez-Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Alberto","family":"Alonso-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Lopez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7637-7283","authenticated-orcid":false,"given":"Alberto","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6781-3362","authenticated-orcid":false,"given":"Pablo","family":"Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Garcia-Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-2597","authenticated-orcid":false,"given":"David","family":"Perez-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jimenez-Ubieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier de la","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4863","authenticated-orcid":false,"given":"Mar\u00eda","family":"Calbacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2025.10.021_bib0001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jtct.2021.09.024","article-title":"Benefits of autologous stem cell transplantation for elderly myeloma patients in the last quarter of life","volume":"28","author":"Joseph","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.10.021_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age \u2265 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.021_bib0003","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2022-158484","article-title":"What is the benefit of autologous stem cell transplantation in multiple myeloma beyond the age of 65? Inputs from real-world data in the Emmy cohort","volume":"140","author":"Perrot","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2025.10.021_bib0004","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1016\/j.clml.2025.10.021_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.10.021_bib0006","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.10.021_bib0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1016\/j.clml.2025.10.021_bib0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.10.021_bib0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"10068","key":"10.1016\/j.clml.2025.10.021_bib0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clml.2025.10.021_bib0011","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.021_bib0012","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.10.021_bib0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.021_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.clml.2025.10.021_bib0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jtct.2024.06.001","article-title":"Trends in outcomes after upfront autologous transplant for multiple myeloma over three decades","volume":"30","author":"Pasvolsky","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.10.021_bib0016","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2025.10.021_bib0017","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.021_bib0018","article-title":"Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review","volume":"14","author":"Tang","year":"2024","journal-title":"Front Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.10.021_bib0019","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.10.021_bib0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-018-3528-x","article-title":"Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"98","author":"Marini","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.021_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.021_bib0022","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.bmt.1702188","article-title":"The role of autologous transplantation in patients with multiple myeloma aged 65 years and over","volume":"25","author":"Sirohi","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.10.021_bib0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jtct.2021.09.024","article-title":"Benefits of autologous stem cell transplantation for elderly myeloma patients in the last quarter of life","volume":"28","author":"Joseph","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.clml.2025.10.021_bib0024","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.021_bib0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.10.021_bib0026","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.13804","article-title":"Autologous stem cell transplantation in multiple myeloma patients over 70 years: a GIMEMA Lazio Working Group experience in a retrospective case-control study","volume":"109","author":"Rago","year":"2022","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.021_bib0027","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"6","key":"10.1016\/j.clml.2025.10.021_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00692-8","article-title":"Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network","volume":"12","author":"Sanz","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.10.021_bib0029","first-page":"1","article-title":"Large-scale real-life analysis of survival and usage of therapies in multiple myeloma","volume":"16","author":"Lopez-Mu\u00f1oz","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.021_bib0030","first-page":"272","article-title":"Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses","volume":"109","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2025.10.021_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00588-z","article-title":"Impact of COVID-19 in patients with multiple myeloma based on a global data network","volume":"11","author":"Martinez-Lopez","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.021_bib0032","article-title":"Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens","volume":"109","author":"Baden","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.10.021_bib0033","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02151-w","article-title":"Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study","volume":"19","author":"Nguyen","year":"2021","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.clml.2025.10.021_bib0034","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.8471","article-title":"A causal framework for classical statistical estimands in failure-time settings with competing events","volume":"39","author":"Young","year":"2020","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.clml.2025.10.021_bib0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.clml.2025.10.021_bib0036","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis","volume":"5","author":"Pu\u00e9chal","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2022","key":"10.1016\/j.clml.2025.10.021_bib0037","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jclinepi.2022.10.005","article-title":"Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: systematic bias assessment of ovarian cancer treatment effectiveness","volume":"152","author":"Kuehne","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.021_bib0038","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age \u2265 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:19:10Z","timestamp":1770650350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042661"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}